The utility of targeting CDK11 is further supported by a recent investigation using intratumoral delivery of naked siRNAs in osteosarcoma xenograft tumors that demonstrated the efficacy of reduced CDK11 expression in this model [15]. The gene discussed is CDK19; the disease is osteosarcoma.